

620-445
AHB/LP6392054

Nixon & Vanderhye P.C. (10/99)
(Domestic Non-Assigned/Foreign) Page 1

RULE 63 (37 C.F.R. 1.63)
INVENTORS DECLARATION FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, mailing address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS

the specification of which (check applicable box(es)):

☐ is attached hereto
☒ was filed on July 24, 2006 as U.S. Application Serial No. (Atty. Dkt. No. 620-445)
☒ was filed as PCT International application No. PCT/EP2005/000937 on 27 January 2005
and (if applicable to U.S. or PCT application) was amended on 24 July 2006

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose to the Patent Office all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):	Application Number	Country	Day/Month/Year Filed
	0401876.8	GB	28 January 2004




I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below:

Prior U.S./PCT Application(s):	Application Serial No.	Day/Month/Year Filed	Status: patented pending, abandoned
	PCT/EP2005/000937	27 January 2005	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And on behalf of the owner(s) hereof, I hereby appoint Nixon & Vanderhye P.C., telephone number 703-816-

4000 (to whom all communications are to be directed) and the attorneys of: **Customer Number 23117**, individually and collectively owner's/owners' attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent. I also authorize Nixon & Vanderhye to add or delete attorneys from that Customer Number, and to act and rely solely on instructions directly communicated from the person, assignee, attorney, firm, or other organization sending instructions to Nixon & Vanderhye on behalf of the owner(s).

1.	Inventor's Signature: Inventor:		Date: November 21 2006
	Residence: (city)	Amsterdam	The Netherlands
	Mailing Address:	Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands	
	(Zip Code)	NL-1066 CX	
2.	Inventor's Signature: Inventor:		Date: November 21 2006
	Residence: (city)	Amsterdam	The Netherlands
	Mailing Address:	Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands	
	(Zip Code)	NL-1066 CX	
3.	Inventor's Signature: Inventor:		Date: November 21 2006
	Residence: (city)	Amsterdam	The Netherlands
	Mailing Address:	The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands	
	(Zip Code)	NL-1066 CX	